Recently, the company completed a Series B financing of 100 million yuan, led by Langzi Hanya, Jinggangshan Zhendong Shenghong Investment, Yangzhou Kaixian Venture Capital, and old shareholders. This round of financing will help Mengyang Pharmaceutical's rapid development, consolidate the company's product structure, and expand the company's research and development pipeline.

The company has always been a modern high-tech pharmaceutical enterprise with the mission of "improving the quality of life of cancer patients", focusing on solving "tumor treatment-related diseases". Since its establishment, it has been committed to exploring the treasure of traditional Chinese medicine, developing classic formulas of famous traditional Chinese medicine and effective ingredients from natural drugs into drugs that meet clinical needs. The company's team all come from senior technical talents in the industry, with deep experience accumulation and leading technological advantages in the pharmaceutical field. Star product "Shengbai Oral Liquid" As a well-known traditional Chinese medicine formula used for the treatment of leukopenia caused by radiotherapy and chemotherapy, it can be evaluated using quantitative indicators and included in the national pharmacopoeia. It has been included in multiple clinical application guidelines and expert consensus, and has obtained an international PCT patent. It has now started the model of Chinese medicine going abroad and officially cooperated with Sutter Hospital in Southern California, USA to initiate the admission process of the hospital. Currently, the company has multiple projects under research and development, and the R&D pipeline covers the hospital Prevention of chemotherapy induced cardiac toxicity, cancer-related fatigue, drug-induced liver injury, treatment of late stage opioid constipation, elevated platelets, and other tumor related diseases.

This financing will mainly be used to promote the phase II clinical research of the company's investigational product - the world's first oral cardioprotective agent for preventing doxorubicin cardiotoxicity - DH001, as well as the research on new indications for already marketed products and the expansion of the company's product line.

Zhang Min, Chairman of Mengyang Pharmaceutical, stated:

The trend of "slow progression" of tumor diseases is obvious, and "survival with tumors" will become the norm. The various toxic side effects of anti-tumor drugs pose great potential risks to the lives of patients and seriously affect their quality of life. The company has been deeply involved in the field of "tumor treatment related diseases", expanding its research and development pipeline. By the end of 2021, it was favored by the A-round investor Renjifan Capital. DH001 has demonstrated very good safety and tolerability data in Phase I clinical trials, with high oral utilization. Currently, Phase II clinical trials are progressing smoothly.

Thank you very much to all investors for their attention and support to Mengyang Pharmaceutical. I believe that the B-round financing has received joint investment from Beijing Langzi Hanya Asset Management, Jinggangshan Zhendong Shenghong Investment, Yangzhou Kaixian Venture Capital, and old shareholders, which will accelerate the clinical trials and product launch of DH001. We look forward to seeing DH001 demonstrate good therapeutic effects in subsequent clinical studies and benefit cancer patients as soon as possible.

Leading investor Lang Zi Han Ya stated:

Langzi Hanya Asset Management is the first Sino Korean Japanese joint venture asset management institution in China, with a total managed capital of 48.8 billion yuan. Life and health have always been a key focus of the company's equity investment business. This investment in Mengyang Pharmaceutical's layout of the cancer related disease treatment track is not only optimistic about Mengyang Pharmaceutical's forward-looking technology, pipeline, and product layout around the field of cancer treatment related diseases. At the same time, it is also optimistic about the core team and commercialization ability of Mengyang Pharmaceutical. The company has a clear positioning and a clear track, inheriting the essence on the basis of famous traditional Chinese medicine prescriptions, and maintaining integrity and innovation. We sincerely look forward to Mengyang Pharmaceutical maintaining a high-speed development trend and becoming a leading enterprise in the field of "tumor treatment related diseases"!